What antibiotics are used to treat neutropenic fever (fever in the setting of neutropenia, a condition characterized by a low neutrophil count)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For neutropenic fever, the recommended initial antibiotic regimen is monotherapy with an anti-pseudomonal beta-lactam, such as cefepime, meropenem, or piperacillin-tazobactam, as outlined in the guidelines by the Infectious Diseases Society of America 1.

Key Considerations

  • The goal of initial empirical antibiotic therapy is to prevent serious morbidity and mortality due to bacterial pathogens, until the results of blood cultures are available to guide more precise antibiotic choices 1.
  • High-risk patients require hospitalization for IV empirical antibiotic therapy, with monotherapy with an anti-pseudomonal beta-lactam agent being recommended 1.
  • Vancomycin is not recommended as a standard part of the initial antibiotic regimen for fever and neutropenia, but may be considered for specific clinical indications, such as suspected catheter-related infection or hemodynamic instability 1.

Recommended Antibiotic Regimens

  • Cefepime: 2 g IV every 8 hours
  • Meropenem: 1 g IV every 8 hours
  • Piperacillin-tazobactam: 4.5 g IV every 6 hours

Additional Considerations

  • If the patient is critically ill, has severe sepsis, or is at high risk for resistant organisms, consider adding vancomycin: 15-20 mg/kg IV every 8-12 hours 1.
  • Adjust therapy based on culture results and clinical response, and consider antifungal coverage if fever persists after 4-7 days of broad-spectrum antibiotics 1.

Importance of Early Treatment

  • Early and aggressive treatment is crucial to prevent rapid progression of infection in these immunocompromised patients, as highlighted in the guidelines by the Infectious Diseases Society of America 1.

From the FDA Drug Label

The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials comparing cefepime monotherapy (at a dose of 2 g intravenously every 8 hours) to ceftazidime monotherapy (at a dose of 2 g intravenously every 8 hours). These studies comprised 317 evaluable patients For all outcome measures, cefepime was therapeutically equivalent to ceftazidime

  • Cefepime and ceftazidime are used to treat neutropenic fever, as they have been shown to be therapeutically equivalent in clinical trials 2.
  • These antibiotics are used as empiric monotherapy for febrile neutropenic patients.

From the Research

Antibiotics Used to Treat Neutropenic Fever

The following antibiotics are used to treat neutropenic fever:

  • Trimethoprim-sulfamethoxazole 3
  • Quinolones 3
  • Ceftazidime and Amikacin 4
  • Piperacillin, gentamicin and cefazolin 5
  • Piperacillin/tazobactam 5
  • Imipenem 5
  • Cefepime, piperacillin-tazobactam, and meropenem 6

Considerations for Antibiotic Selection

When selecting antibiotics for neutropenic fever, the following factors should be considered:

  • Risk of complications following infection 7
  • Presence of gram-positive or gram-negative bacteria 4
  • Resistance patterns of the bacteria 6
  • Patient's underlying condition and medical history 7

Antibiotic Resistance

Antibiotic resistance is a significant concern in the treatment of neutropenic fever:

  • Pseudomonas aeruginosa is commonly resistant to antibiotics recommended in international guidelines 6
  • Inappropriate empirical antibiotic treatment is associated with higher mortality 6, 5
  • Broad-spectrum antibiotic combinations may maximize coverage among neutropenic patients 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antimicrobial prophylaxis in febrile neutropenia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004

Research

Response of first-line antibiotic therapy in patients with febrile neutropenia during treatment of hematological disorders.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2015

Research

Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.

The Korean journal of internal medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.